Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person's risk ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

A new drug called lepodisiran may offer hope to millions of people at risk of heart attacks and strokes by targeting a little ...

A dose of an experimental drug reduced the levels of a fatal type of cholesterol for up to a year despite previous knowledge that it's untreatable. NBC News reported that pharmaceutical company Eli ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent.

Eli Lilly’s experimental drug lepodisiran has shown a 94% reduction in lipoprotein(a) levels, a key genetic risk factor for ...

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...